GBI Research Market Research Reports

Title published price

Psoriasis Therapeutics in Asia-Pacific Markets to 2024 - Increasing Prevalence, Advent of Novel Biologics and Pipeline Drugs to Drive the Market

By GBI Research

Psoriasis is a common, chronic inflammatory skin condition affecting around 2-3% of the world’s population. While the main cause of psoriasis remains uncertain, immunologic, genetic, and environmental factors appear to play a role. Common sy ...

01-Jun-2018 $4995

Mosquito-borne Diseases Drug Development Pipeline Review, 2018

By GBI Research

Mosquito-borne Diseases Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for mosquito-borne diseases and comprehensive information on the therapeutics under developmen ...

24-May-2018 $3995

Ocular Cancer Drug Development Pipeline Review, 2018

By GBI Research

Ocular Cancer Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for ocular cancer and comprehensive information on the therapeutics under development and key players in ...

23-May-2018 $3995

Inflammatory Skin Diseases Drug Development Pipeline Review, 2018

By GBI Research

Inflammatory Skin Diseases Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for inflammatory skin disorders and comprehensive information on the therapeutics under dev ...

22-May-2018 $3995

Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms

By GBI Research

Frontier Pharma: Schizophrenia - Diverse First-in-Class Pipeline Shows Promise for Treatment of Negative and Cognitive Symptoms Summary Schizophrenia is a chronic mental disorder that affects 1% of the population - equivalen ...

01-May-2018 $6995

Breast Cancer Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Increasing Uptake of Targeted Therapies and Rising Prevalence

By GBI Research

Breast cancer is the second most common cancer in the world overall, and the most common cancer in women. When diagnosed at a very early stage, the prognosis is positive, with a five-year survival rate of nearly 90%. However, in the later stages o ...

01-May-2018 $4995

Influenza A Viral Infections Drug Development Pipeline Review, 2018

By GBI Research

This report provides an overview of the pipeline landscape for influenza A viral infections. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for influenza A H3N2, H1N1 ...

30-Apr-2018 $3995

Cognitive Impairment Disorders Drug Development Pipeline Review, 2018

By GBI Research

Cognitive Impairment Disorders Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for cognitive impairment disorders. It provides comprehensive information on the therap ...

01-Apr-2018 $3995

Frontier Pharma: Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease

By GBI Research

Frontier Pharma: Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease Summary ...

01-Apr-2018 $6995

HAE Therapeutics in Asia-Pacific Markets to 2023 - Growth Driven by Ongoing Shift towards Plasma-Derivative Products and Expected Launch of Premium Therapies

By GBI Research

Hereditary Angioedema (HAE) is a rare genetic disorder caused by a lack of a sufficient amount of a protein called C1 esterase inhibitor (C1-INH), which plays a role in immune system function, blood clotting, and bleeding. With insufficient C1-INH ...

31-Mar-2018 $4995

Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs

By GBI Research

Summary Immune-mediated inflammatory diseases are a common set of chronic disorders that affect 5-7% of people in Western populations. Although they are often disparate in terms of their symptoms and key p ...

31-Mar-2018 $4995

Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018

By GBI Research

This report provides an overview of the pipeline landscape for the respiratory tract infections respiratory syncytial virus (RSV) and human parainfluenza virus 3 (HPIV-3).It provides comprehensive information on the therapeutics under ...

30-Mar-2018 $3995

Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018

By GBI Research

This report provides an overview of the non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players acti ...

22-Mar-2018 $3995

Fungal Foot Infections Drug Development Pipeline Review, 2018

By GBI Research

Summary This report provides an overview of the fungal foot infection pipeline landscape. It provides comprehensive information on the therapeutics under development for onychomycosis (Tinea unguium) and athlete's foot (Ti ...

22-Mar-2018 $3995

Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs

By GBI Research

Summary Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion over many year ...

01-Mar-2018 $4995

Global Neurodegenerative Diseases Drugs Market to 2023 - MS Set to Dominate with Tecfidera and Ocrevus, as Disease-Modifying Pipeline Therapies for Alzheimer’s Disease and SMA Show Clinical and Commercial Potential

By GBI Research

Summary Neurodegenerative diseases are becoming increasingly prevalent due to an aging population, but this diverse therapy area remains largely untreatable with current therapies. Neurodegenerative diseases are ch ...

07-Feb-2018 $4995

Antibacterial Therapeutics - High levels of Pipeline Innovation Focused on the Increasing Unmet Need Associated with Antibiotic Resistance

By GBI Research

Summary Antibacterial resistance is currently believed to be responsible for over 700,000 deaths each year. As antibiotic resistance increases, due to the overuse and misuse of antibiotics, the number of avoidable deaths i ...

01-Feb-2018 $6995

Frontier Pharma: Women's Health - An Expanding Therapy Area, with Endometriosis Therapies Prominent among the First-in-Class Pipeline

By GBI Research

Frontier Pharma: Women's Health - An Expanding Therapy Area, with Endometriosis Therapies Prominent among the First-in-Class Pipeline Summary The women's health therapy area covers medical disorders that affect females only, ...

01-Feb-2018 $6995

Uveitis Therapeutics in Asia-Pacific Markets to 2023 - Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs to Drive the Market

By GBI Research

Uveitis Therapeutics in Asia-Pacific Markets to 2023 - Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs to Drive the Market Summary Uveitis refers to inflammation of the uvea, the middle vascular ...

01-Feb-2018 $4995

Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017

By GBI Research

This report provides an overview of the Lower Female Reproductive System Cancers pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Cervic ...

26-Jan-2018 $3995